Last updated 2026-06-18
- Acquired by Chemomab Therapeutics, Mar 2021
- Raised $4.7M funding round, Oct 2016
- Raised $4M funding round, Nov 2012
Total raised
$37.7M
Last: 2016-10
Stage
Acquired
Founded
2004
Headcount
1-10
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat cancer-related diseases. Its most advanced product candidate, BC-819, is under development as a treatment for non-muscle-invasive bladder cancer. Anchiano also develops a second-generation drug, BC-821, for the systemic treatment of advanced malignant neoplasms. Preclinical studies of BC-821 have showed significant efficacy in different cancer animal models, such as metastatic lung cancer and metastatic liver cancer. AnchianoTherapeutics is a direct subsidiary of Clal Biotechnology Industries Ltd.
Funding history · 2 rounds · $37.7M total
2016-10
2012-11
Q&A
- What is Anchiano Therapeutics' primary focus?
- Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat cancer-related diseases.
- What is Anchiano Therapeutics' most advanced product candidate?
- Anchiano Therapeutics' most advanced product candidate is BC-819, which is under development as a treatment for non-muscle-invasive bladder cancer.
- Does Anchiano Therapeutics have a second-generation drug in development?
- Yes, Anchiano Therapeutics is developing BC-821, a second-generation drug for the systemic treatment of advanced malignant neoplasms. Preclinical studies have shown its efficacy in various cancer animal models.
- When was Anchiano Therapeutics acquired and by whom?
- Anchiano Therapeutics was acquired by Chemomab Therapeutics in March 2021.
- What is the total amount of funding Anchiano Therapeutics raised?
- Anchiano Therapeutics raised a total of $37.7 million USD.
- Which company is a direct subsidiary of Clal Biotechnology Industries Ltd.?
- Anchiano Therapeutics is a direct subsidiary of Clal Biotechnology Industries Ltd.
- How many employees does Anchiano Therapeutics have?
- Anchiano Therapeutics has 1-10 employees.
- Who is the Co-Founder and Chief Scientist of Anchiano Therapeutics?
- Prof. Avraham Hochberg (Late) is the Co-Founder and Chief Scientist of Anchiano Therapeutics.
Team · 1
Founder · Co-Founder & Chief Scientist
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentMedical DevicesMedical Treatment & Therapeutics
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
cancerbiotechnologybiopharmaceuticalcell-therapybiopsytargeted-therapypharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/33255574 |
Identifiers & details
| Former names | BioCancell Therapeutics |
|---|---|
| Founded | 2004-10 |
| Offices | Cambridge |
| Status reason | Acquired (Inactive) by Chemomab Therapeutics on Mar 2021 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Chemomab Therapeutics 2021-03